Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ABSI vs ARVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARVN Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 6–4 Matrix Metrics)

ARVN Overall Winner 6-Pillar Tally: ABSI 1 – 3 ARVN (2 Tie) Matrix Metrics: ABSI 4 – 6 ARVN

As of Nov 16, 2026, Arvinas, Inc (ARVN) is the stronger overall head-to-head candidate over Absci Corporation (ABSI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ABSI carries a Unified Composite Score of 41.2/100 (SELL) at $7.58 (N/M Forward P/E, -9108.3% operating margin), whereas ARVN carries 52.9/100 (HOLD) at $6.74 (17.9x Forward P/E, -10.1% operating margin).

  • Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. ABSI 41.2/100 SELL) and 1.40β · 66% Vol risk profile, whereas ABSI leads top-line expansion (-19.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ABSI is currently in a Breakdown options structure phase (RSI 38.8); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABSI vs ARVN
ABSI NASDAQ
Absci Corporation Common Stock
Services-Commercial Physical & Biological Research
$7.58
-10.36% 1D
Market Cap $1.6B
TTM Revenue $1.5M
Forward P/E N/M
Beta / 30D Vol 3.32β · 127% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 30.0 Fund 51.0 Flow 71.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.8 · SMA20: $9.94 · SMA50: $9.63
ARVN NASDAQ Head-to-Head Winner
Arvinas, Inc
Pharmaceutical Preparations
$6.74
-1.17% 1D
Market Cap $449.9M
TTM Revenue $275M
Forward P/E 17.9x
Beta / 30D Vol 1.40β · 66% Vol
Unified Composite Score
52.9 / 100 HOLD
Tech 54.0 Fund 59.0 Flow 71.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.6%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $7.22 · SMA50: $7.57

6-Pillar Scorecard Institutional Category Breakdown (ABSI 1 – 3 ARVN)

Columns: Metric · ABSI · ARVN
1. Valuation Multiples ARVN
Forward P/E N/M 17.9x
Trailing P/E N/M 17.9x
PEG Ratio N/M N/M
EV / Revenue N/M 1.3x
2. Growth & Scale ABSI
Revenue Growth (YoY) -19.6% -98.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.5M $275M
Market Cap $1.6B $449.9M
3. Profitability & Quality ARVN
Gross Margin N/A 96.7%
Operating Margin -9108.3% -10.1%
Net Profit Margin 0.0% -3.5%
Return on Equity (ROE) -58.6% -1.8%
4. Balance Sheet & Cash Flow ARVN
Cash Generation (TTM) -$112M -$160M
Cash Flow Margin N/A -58.0%
Net Cash / Leverage $10M Net Cash $81M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 169.1% (15th %ile) 108.7% (25th %ile)
Put/Call OI Skew 0.57x (Call-Skewed) 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABSI (4) vs ARVN (6)
Institutional Metric ABSI ARVN Criterion Row Edge
Market Capitalization
Scale
$1.6B $449.9M Larger Scale ABSI
Trailing P/E Ratio
Valuation
N/M 17.9x Lower Multiple ARVN
Forward P/E Ratio
Valuation
N/M 17.9x Lower Multiple ARVN
Revenue Growth (YoY)
Growth
-19.6% -98.8% Higher Growth ABSI
Operating Margin (TTM)
Profitability
-9108.3% -10.1% Higher Margin ARVN
Net Profit Margin
Profitability
0.0% -3.5% Higher Margin ABSI
Return on Equity (ROE)
Capital Efficiency
-58.6% -1.8% Higher ROE ARVN
52-Week Range Position
Momentum
52% ($2–$13) 5% ($6–$15) Stronger Trend ABSI
Beta / 30D Volatility
Risk Regime
3.32β · 127% Vol 1.40β · 66% Vol Lower Realized Risk ARVN
Unified Institutional Score
Composite Signal
41.2 / 100 (SELL) 52.9 / 100 (HOLD) Higher Composite ARVN
Trailing 12M Revenue (USD)
Operating Scale
$1.5M $275M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 96.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$112M ($10M Net Cash) -$160M ($81M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ARVN +4.88 pp
ABSI: -8.18% · ARVN: -3.3%
3M Horizon ABSI +12.8 pp
ABSI: -14.41% · ARVN: -27.21%
6M Horizon ABSI +76.42 pp
ABSI: +53.19% · ARVN: -23.23%
1Y Horizon ABSI +220.33 pp
ABSI: +186.93% · ARVN: -33.4%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ABSI Revenue ARVN Revenue ABSI Op. Margin ARVN Op. Margin Margin Leader
FY2018 N/A $10M N/A -306.3% ARVN
FY2019 N/A $20M N/A -281.4% ARVN
FY2020 $0M $20M -278.3% -554.1% ABSI
FY2021 $0M $50M -1573.4% -403.4% ARVN
FY2022 $10M $130M -1857.5% -200.3% ARVN
FY2023 $10M $80M -2020.2% -511.5% ARVN
FY2024 $0M $260M -2401.6% -95.0% ARVN
FY2025 $0M $260M -4297.0% -45.1% ARVN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABSI BREAKDOWN
97d in phase · OBV NEUTRAL
Current IV 169.1%
IV Percentile 15th %ile
Put/Call OI Skew 0.57x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ABSI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ARVN BREAKDOWN
62d in phase · OBV DISTRIBUTION
Current IV 108.7%
IV Percentile 25th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ARVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABSI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.6B market capitalization and -9108.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ARVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $449.9M market capitalization and -10.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABSI vs ARVN Key Questions & Quantitative Answers

As of Nov 16, 2026, Arvinas, Inc (ARVN) is the stronger overall head-to-head candidate over Absci Corporation (ABSI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). ABSI carries a Unified Composite Score of 41.2/100 (SELL) at $7.58 (N/M Forward P/E, -9108.3% operating margin), whereas ARVN carries 52.9/100 (HOLD) at $6.74 (17.9x Forward P/E, -10.1% operating margin). Growth vs. Quality Trade-Off: ARVN earns the overall head-to-head edge with a stronger Unified Composite Score (52.9/100 HOLD vs. ABSI 41.2/100 SELL) and 1.40β · 66% Vol risk profile, whereas ABSI leads top-line expansion (-19.6% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ABSI is currently in a Breakdown options structure phase (RSI 38.8); meanwhile ARVN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ABSI leads the Growth & Scale pillar: ABSI posts -19.6% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (N/A gross margin, -9108.3% operating margin), compared with ARVN at -98.8% YoY revenue growth and +0.0% YoY earnings growth on $275M TTM revenue (96.7% gross margin, -10.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ABSI cumulative revenue shifted +0.0% while ARVN shifted +2500.0%. In operating R&D and SG&A reinvestment, ABSI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARVN.

ARVN screens cheaper on headline valuation multiples. ABSI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ARVN trades at 17.9x Forward P/E, 17.9x Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-58.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABSI (-58.6% ROE) versus ARVN (-1.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ABSI carries 169.1% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.32β · 127% Vol realized risk). By comparison, ARVN carries 108.7% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.40β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.